Here we highlight a subset of our preferred stocks from the screener.<\/p>\n
Overview: Amper, S.A. operates in the defense and national security, as well as energy and sustainability sectors both in Spain and internationally, with a market cap of \u20ac387.40 million.<\/p>\n
Operations: The company’s revenue is primarily derived from its Energy and Sustainability segment, which generated \u20ac165.21 million, and its Defense, Security and Telecommunications segment, contributing \u20ac120.41 million.<\/p>\n
Estimated Discount To Fair Value: 40.1%<\/p>\n
Amper is trading at \u20ac0.17, below its estimated future cash flow value of \u20ac0.28, indicating undervaluation by more than 20%. Despite a volatile share price and recent shareholder dilution, Amper’s earnings are expected to grow significantly at 49.6% annually over the next three years, surpassing the Spanish market growth rate. However, challenges include a decline in sales from \u20ac419.47 million to \u20ac281.73 million last year and low projected return on equity of 14.6%.<\/p>\n
Overview: Harvia Oyj designs, manufactures, and markets a range of sauna products worldwide with a market cap of \u20ac653.12 million.<\/p>\n Operations: The company’s revenue segments include the design, manufacturing, and marketing of various sauna products globally.<\/p>\n Estimated Discount To Fair Value: 46.5%<\/p>\n Harvia Oyj, trading at \u20ac34.95, is valued 46.5% below its estimated future cash flow value of \u20ac65.29, suggesting significant undervaluation. The company’s earnings are forecast to grow 14.9% annually, outpacing the Finnish market’s growth rate of 12.7%. Recent earnings reports show increased sales and net income for both the fourth quarter and full year of 2025, while Harvia seeks strategic acquisitions to bolster growth amidst volatile market conditions.<\/p>\n Overview: Apotea AB (publ) operates an online pharmacy in Sweden with a market capitalization of SEK6.75 billion.<\/p>\n Operations: The company generates revenue of SEK7.21 billion from its online retail operations in Sweden.<\/p>\n Estimated Discount To Fair Value: 49.8%<\/p>\n Apotea AB, trading at SEK 64.85, is valued 49.8% below its estimated future cash flow value of SEK 129.21, highlighting potential undervaluation. Despite a slower revenue growth forecast of 12.5% annually compared to the Swedish market’s modest 0.9%, Apotea’s earnings are expected to grow significantly by over 20% per year, surpassing the market average of 9.8%. Recent board changes aim to enhance strategic growth and customer experience initiatives.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include BME:AMP HLSE:HARVIA and OM:APOTEA.<\/p>\n This article was originally published by Simply Wall St<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The European stock market has recently experienced a notable upswing, with the pan-European STOXX Europe 600 Index rising…\n","protected":false},"author":2,"featured_media":13994,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[10931,518,15,350,1084,10201,517],"class_list":{"0":"post-13993","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-europe","8":"tag-apotea","9":"tag-cash-flows","10":"tag-european","11":"tag-fair-value","12":"tag-market-inefficiencies","13":"tag-sp-group","14":"tag-undervalued-stocks"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/13993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/comments?post=13993"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/13993\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media\/13994"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media?parent=13993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/categories?post=13993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/tags?post=13993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"BME:AMP](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/04\/36fa708f9ffa272003e7a9dfab51b6c0.png\")
<\/a> BME:AMP Discounted Cash Flow as at Apr 2026 <\/p>\n<\/a> HLSE:HARVIA Discounted Cash Flow as at Apr 2026 <\/p>\n
<\/a> OM:APOTEA Discounted Cash Flow as at Apr 2026 <\/p>\n